Prostate Cancer | Specialty

Off-the-Shelf Immunotherapy ADXS-504 Under Evaluation in Biochemically Recurrent Prostate Cancer

May 12th 2021

Columbia University Irving Medical Center will partner with Advaxis, Inc. to fund a phase 1 clinical trial that seeks to examine the novel off-the-shelf neoantigen immunotherapy agent ADXS-504 in patients with biochemically recurrent prostate cancer.

FDA Grants Breakthrough Device Designation to AI-Based Focal Therapy System in Prostate Cancer

May 11th 2021

The FDA has granted a breakthrough device designation to the Avenda Health Focal Therapy System, a male “lumpectomy” product under development to treat patients with prostate cancer in office while preserving quality of life.

Dr. Zhu on Stratifying Treatments in Node-Positive Prostate Cancer

May 10th 2021

Jason Zhu, MD, discusses the process of stratifying treatments for patients with node-positive prostate cancer.

Enzalutamide Approved in Europe for Metastatic Hormone-Sensitive Prostate Cancer

May 4th 2021

The European Commission has approved enzalutamide for the treatment of adult patients with metastatic hormone-sensitive prostate cancer.

Masitinib Plus Docetaxel Improves PFS in Metastatic Castration-Resistant Prostate Cancer

April 30th 2021

The novel oral TKI masitinib in combination with docetaxel and prednisone resulted in improved progression-free survival compared with docetaxel plus prednisone in patients with metastatic castration-resistant prostate cancer, meeting the predefined primary end point of the phase 2b/3 AB12003 trial.

PARP Inhibitors Pave Way for Personalized Care in CRPC

April 30th 2021

Earle F. Burgess, MD, discusses optimizing the use of PARP inhibitors in the treatment of patients with advanced prostate cancer.

Increased Somatically Acquired Alterations May Lead to More Aggressive Prostate Cancer, Mortality in Black Patients

April 29th 2021

A higher incidence of somatically acquired genetic alterations, including damaging mutations in ZMYM3 leading to genomic instability, as well as deletions in MAP3K7, BNIP3L, RB1, and NEIL3, and gain of MYC, may lead to more aggressive prostate cancer in Black/African American men.

Dr. Choudhury on Future Research Directions for Pembrolizumab/Radium-223 in mCRPC

April 26th 2021

Atish D. Choudhury, MD, PhD, discusses future research directions for the combination of pembrolizumab and radium-223 dichloride in patients with metastatic castration-resistant prostate cancer.

Apalutamide Maintains OS Benefit in Castration-Sensitive Prostate Cancer

April 26th 2021

Apalutamide plus androgen deprivation therapy maintained an overall survival advantage over placebo for a broad population of patients with metastatic castration-sensitive prostate cancer after nearly 4 years of median follow-up.

Earlier Administration of Antiandrogens May Further Delay Disease Progression in Nonmetastatic CRPC

April 26th 2021

Natasha Garg, DO, discusses the impact of antiandrogens in the treatment of patients with nonmetastatic CRPC, shared advice for choosing among the available options, and projected what the future paradigm might look like.